VRNA - Verona Pharma plc

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Verona Pharma plc

3 More London Riverside
London SE1 2RE
United Kingdom
44 20 3283 4200

Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Dr. Jan-Anders KarlssonCEO & Exec. DirectorN/AN/A1955
Mr. Piers John MorganChief Financial OfficerN/AN/A1966
Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIAGen. CounselN/AN/A1967
Ms. Victoria StewartDirector of CommunicationsN/AN/AN/A
Dr. Peter SpargoSr. VP of Chemistry Manufacturing & ControlsN/AN/A1962
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler formulation and a pressurized metered-dose inhaler formulation, which are in Phase II clinical trials. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

Corporate Governance

Verona Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.